SCHEMBL22718276

SCHEMBL22718276

COc1ccc(CN(C)S(=O)(=O)c2ccc(Nc3ccc(C#N)cn3)c(-c3cn(C)cn3)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR6 P51684 2/20 0.41
▸ TEAD1 P28347 1/20 0.37
▸ YAP1 P46937 1/20 0.37
▸ EP300 Q09472 2/20 0.36
▸ KAT8 Q9H7Z6 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ MAPK8 P45983 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ FNTA P49354 1/20 0.34
▸ FNTB P49356 1/20 0.34
▸ PGGT1B P53609 1/20 0.34
▸ IDH1 O75874 2/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ CYP19A1 P11511 2/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ TYK2 P29597 1/20 0.34
▸ STAT3 P40763 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438849 1.00 CCR6 (0.41) CCR6TEAD1YAP1EP300KAT8
SCHEMBL24496182 0.89 TEAD1 (0.39) TEAD1YAP1KAT8MEN1KMT2A
SCHEMBL29648333 0.89 TEAD1 (0.39) TEAD1YAP1KAT8MEN1KMT2A
SCHEMBL24495997 0.88 TSHR (0.38) TEAD1YAP1KAT8MEN1KMT2A
SCHEMBL29648312 0.88 TSHR (0.38) TEAD1YAP1KAT8MEN1KMT2A
SCHEMBL24496062 0.87 TEAD1 (0.37) TEAD1YAP1KAT8MEN1KMT2A
SCHEMBL22718047 0.87 TEAD1 (0.42) TEAD1YAP1KAT8MEN1KMT2A
SCHEMBL24496012 0.87 BMP1 (0.39) TEAD1YAP1KAT8MEN1KMT2A
SCHEMBL22718097 0.87 TEAD1 (0.42) CCR6TEAD1YAP1KAT8MEN1
SCHEMBL29438890 0.87 TEAD1 (0.42) TEAD1YAP1KAT8MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2024-03-14 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2022-08-11 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885TEAD1 4/4885YAP1 111/4885
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 CCR6 4335/4885TEAD1 4/4885YAP1 111/4885
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885TEAD1 4/4885YAP1 111/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 CCR6 4335/4885TEAD1 4/4885YAP1 111/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 CCR6 2313/4885TEAD1 7/4885YAP1 13/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885TEAD1 4/4885YAP1 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback